219 related articles for article (PubMed ID: 12194388)
1. Progress toward gene therapy of Duchenne muscular dystrophy.
Hartigan-O'Connor D; Chamberlain JS
Semin Neurol; 1999; 19(3):323-32. PubMed ID: 12194388
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles.
Floyd SS; Clemens PR; Ontell MR; Kochanek S; Day CS; Yang J; Hauschka SD; Balkir L; Morgan J; Moreland MS; Feero GW; Epperly M; Huard J
Gene Ther; 1998 Jan; 5(1):19-30. PubMed ID: 9536261
[TBL] [Abstract][Full Text] [Related]
3. CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle.
Jiang Z; Schiedner G; Gilchrist SC; Kochanek S; Clemens PR
Gene Ther; 2004 Oct; 11(19):1453-61. PubMed ID: 15269713
[TBL] [Abstract][Full Text] [Related]
4. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle.
Akkaraju GR; Huard J; Hoffman EP; Goins WF; Pruchnic R; Watkins SC; Cohen JB; Glorioso JC
J Gene Med; 1999; 1(4):280-9. PubMed ID: 10738561
[TBL] [Abstract][Full Text] [Related]
5. Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells.
Gonçalves MA; Holkers M; Cudré-Mauroux C; van Nierop GP; Knaän-Shanzer S; van der Velde I; Valerio D; de Vries AA
Mol Ther; 2006 May; 13(5):976-86. PubMed ID: 16443396
[TBL] [Abstract][Full Text] [Related]
6. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero.
Bilbao R; Reay DP; Wu E; Zheng H; Biermann V; Kochanek S; Clemens PR
Gene Ther; 2005 Jan; 12(1):39-47. PubMed ID: 15483668
[TBL] [Abstract][Full Text] [Related]
7. Restoration of dystrophin expression in mdx mice by intravascular injection of naked DNA containing full-length dystrophin cDNA.
Liang KW; Nishikawa M; Liu F; Sun B; Ye Q; Huang L
Gene Ther; 2004 Jun; 11(11):901-8. PubMed ID: 14985786
[TBL] [Abstract][Full Text] [Related]
8. Full-length dystrophin gene transfer to the mdx mouse in utero.
Reay DP; Bilbao R; Koppanati BM; Cai L; O'Day TL; Jiang Z; Zheng H; Watchko JF; Clemens PR
Gene Ther; 2008 Apr; 15(7):531-6. PubMed ID: 18273052
[TBL] [Abstract][Full Text] [Related]
9. The future of Duchenne muscular dystrophy gene therapy: shrinking the dystrophin gene.
Roberts M; Dickson G
Curr Opin Mol Ther; 2002 Aug; 4(4):343-8. PubMed ID: 12222872
[TBL] [Abstract][Full Text] [Related]
10. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.
Cerletti M; Negri T; Cozzi F; Colpo R; Andreetta F; Croci D; Davies KE; Cornelio F; Pozza O; Karpati G; Gilbert R; Mora M
Gene Ther; 2003 May; 10(9):750-7. PubMed ID: 12704413
[TBL] [Abstract][Full Text] [Related]
11. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
Athanasopoulos T; Graham IR; Foster H; Dickson G
Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
[TBL] [Abstract][Full Text] [Related]
12. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
[TBL] [Abstract][Full Text] [Related]
13. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
[TBL] [Abstract][Full Text] [Related]
14. Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy.
Athanasopoulos T; Foster H; Foster K; Dickson G
Methods Mol Biol; 2011; 709():21-37. PubMed ID: 21194019
[TBL] [Abstract][Full Text] [Related]
15. [Adeno-associated virus vector carrying human minidystrophin gene SMCKA3999 effectively ameliorates dystrophic pathology in mdx model mice].
Li HH; Zhang SM; Fang SY; Chen CL; Luo YD; Guan Y; Wang DW; Xiao X
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1513-6. PubMed ID: 14521733
[TBL] [Abstract][Full Text] [Related]
16. Autotransplantation in mdx mice of mdx myoblasts genetically corrected by an HSV-1 amplicon vector.
Bujold M; Caron N; Camiran G; Mukherjee S; Allen PD; Tremblay JP; Wang Y
Cell Transplant; 2002; 11(8):759-67. PubMed ID: 12588108
[TBL] [Abstract][Full Text] [Related]
17. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes.
Clemens PR; Kochanek S; Sunada Y; Chan S; Chen HH; Campbell KP; Caskey CT
Gene Ther; 1996 Nov; 3(11):965-72. PubMed ID: 8940636
[TBL] [Abstract][Full Text] [Related]
18. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog.
Koo T; Okada T; Athanasopoulos T; Foster H; Takeda S; Dickson G
J Gene Med; 2011 Sep; 13(9):497-506. PubMed ID: 22144143
[TBL] [Abstract][Full Text] [Related]
19. Gutted adenoviral vector growth using E1/E2b/E3-deleted helper viruses.
Barjot C; Hartigan-O'Connor D; Salvatori G; Scott JM; Chamberlain JS
J Gene Med; 2002; 4(5):480-9. PubMed ID: 12221641
[TBL] [Abstract][Full Text] [Related]
20. Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin.
Li S; Kimura E; Fall BM; Reyes M; Angello JC; Welikson R; Hauschka SD; Chamberlain JS
Gene Ther; 2005 Jul; 12(14):1099-108. PubMed ID: 15759015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]